Header Leaderboard Ad


Cancer genomic testing—barriers to NGS clinical utility



No announcement yet.
  • Filter
  • Time
  • Show
Clear All
new posts

  • Cancer genomic testing—barriers to NGS clinical utility

    Do you wonder why the power of next generation sequencing has not yet been applied to the timely analysis of pharmacogenomic cancer treatment possibilities for a family member, friend, or neighbor? A recently published article from the Jackson Laboratory for Genomic Medicine located in Farmington, Connecticut USA details various issues that are slowing down the applications of next generation sequencing technology to successful precision cancer therapies and comprehensive cancer genomic profiling (1)
    An innovative cancer-related open knowledgebase, JAX-Clinical Knowledgebase (CKB) has also been recently launched to serve as a public resource for translational and clinical researchers. See https://ckb.jax.org
    Users can link tumor sequence information to regularly updated lists of relevant clinical trials in the US actively recruiting subjects and to appropriate, available targeted therapies. The database also includes regularly updated literature references for a growing number of human cancer biomarkers and related genomic information. (2), (3)

    (1) Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic
    DOI: 10.1080/14737159.2017.1319280 (If unavailable in your library, request a copy of this article at [email protected])

    (2) Clinical trials in precision oncology
    DOI: 10.1373/clinchem.2015.247437

    (3) The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies
    DOI: 10.1186/s40246-016-0061-7